Inactive Instrument

ProMIS Neurosciences, Inc. Toronto S.E.

Equities

PMN

CA74346M4065

Biotechnology & Medical Research

ProMIS Neurosciences Inc. Opens an Office in the United States at Cambridge Innovation Center in Cambridge, Massachusetts

January 25, 2016 at 08:15 am

ProMIS Neurosciences Inc. announced that it has opened an office in the United States at Cambridge Innovation Center, 14th floor, 1 Broadway, Cambridge, MA 02142. With this new office the company now has direct access to the vibrant biotechnology and medical science community in the Boston area.

Latest news about ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	04-30	CI
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	04-09	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
ProMIS Neurosciences, Inc. Announces Management Changes	01-03	CI
ProMIS Neurosciences, Inc. Announces CEO Changes	01-03	CI
ProMIS Neurosciences Announces Publication on Novel Target for ALS	12-20	CI
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	11-20	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
BTIG Starts ProMIS Neurosciences With Buy Rating, Price Target is $8	23-10-03	MT
ProMIS Neurosciences Files Mixed Shelf	23-09-25	MT
ProMIS Neurosciences, Inc. announced that it has received $20.483758 million in funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc.	23-08-30	CI
ProMIS Neurosciences Up 48% After Hours as it Raises C$20.4 In a Private Placement of Share Units	23-08-21	MT
ProMIS Neurosciences, Inc. announced that it expects to receive funding from Affinity Asset Advisors, LLC, Ally Bridge Group, Sphera Healthcare US Inc. and others	23-08-20	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI

Chart ProMIS Neurosciences, Inc.

Duration

Period

More charts

Company Profile

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimerâs disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.99%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.78%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs